IRB #

IRB00010529

Title

SARC024: A blanket protocol to study oral regorafenib in patients with refractory
liposarcoma, osteogenic sarcoma, and Ewing/Ewing–like sarcomas

Principal Investigator

Lara Davis

Study Purpose

The purpose of this study is to compare the effects good and/or bad of the study drug, regorafenib, versus placebo on your liposarcoma or bone sarcoma. Another purpose is to study the effects of the study drug on your Ewing-sarcoma to determine the effects, good and/or bad.

Medical Condition(s)

Liposarcoma, Osteogenic sarcoma (bone sarcoma) and Ewing / Ewing- like sarcoma

Eligibility Criteria

Participants 18 and older with liposarcoma, bone sarcoma, or Ewing sarcoma who have had at least one prior form of systemic treatment for their cancer. Screening labs and imaging studies will be done to confirm eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Participants will be in the study for as long as they are seeing clinical benefit.

Minors Included

No

Contact

David Boody-Alter
boodyalt@ohsu.edu
503-418-9655

Sponsor

Sarcoma Alliance for Research through Collaboration (SARC)

Recruitment End

10/01/2021

Compensation Provided

No


Go Back